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Abstract: The highly effective anticancer agent doxorubicin (Dox), is a frontline drug used to 
treat a number of cancers including leukemias, ovarian, prostate, breast, and lung cancer. While 
Dox has a high level of activity against cancer cells, treatment is often complicated by dose-
limiting cardiotoxicity. For many years, this debilitating side effect is thought to originate from 
the drug’s direct activity in the mitochondria of cardiac cells, while recent studies have shown 
that these are primarily downstream effect from nuclear damage. Our lab has developed a 
mitochondrially-targeted derivative of Dox that enables the selective study of toxicity generated 
by the presence of Dox in the mitochondria of H9c2 rat cardiomyocytes. We demonstrate that 
mitochondria-targeted doxorubicin (mtDox) lacks any direct nuclear effects, which allows the 
cardiomyocytes to undergo mitochondrial biogenesis. This recovery response compensates for 
the mitotoxic effects of Dox and prevents cell death in cardiomyocytes. In accordance with these 
findings, cardiac toxicity was only observed in Dox but not mtDox treated mice. This study 
provides valuable insight into the development of methods to effectively limit the debilitating 
cardiotoxic effects of Dox, and potentially of other chemotherapeutics that exert effects on 
multiple subcellular organelles..  
Introduction 
Anthracyclines such as doxorubicin (Dox) are highly effective chemotherapeutic agents 
in widespread use for treatment of a variety of cancers including leukemias, ovarian, breast and 
lung cancer. (1) Since the initial discovery and development of Dox as an antitumor agent in the 
1960s, a variety of cellular mechanisms of its potent cytotoxic activity have been identified. (2) 
The primary mode of action is thought to be through binding at the topoisomerase II (TopoII)-
DNA interface to form covalent TopoII-DNA cleavage complexes, ultimately disrupting DNA 
replication and transcription. (3, 4) Through this process, the formation of TopoII cleavage 
complexes result in the generation of nuclear DNA (nDNA) double stranded breaks (DSBs) 
leading to the induction of apoptosis. In addition, Dox is a redox active compound that can cause 
cell death by generating reactive oxygen species (ROS), which can lead to lipid peroxidation and 
oxidative DNA lesions. 
While Dox is an extremely potent anticancer agent, its clinical use is often complicated 
by dose-limiting cardiotoxicity, causing congestive heart failures in 20% of patients.(5) At the 
cellular level, anthracycline-induced cardiomyopathy has long been associated with 
mitochondrial dysfunction — in particular the generation of high levels of ROS due to redox 
cycling of Dox at complex I of the electron transport chain (ETC).(6, 7) Alterations in iron and 
calcium homeostasis have also been identified as contributing factors. Furthermore, TopoII has 
also been observed in mitochondria(8), although the contributions of mitochondrial 
topoisomerase inhibition to cardiotoxicity have only just begun to be explored.(9) Recently, 
nDNA damage induced by interaction of TopoII was shown to be responsible for the cardiotoxic 
effects of Dox in mouse models.(10, 11) Dox-induced mitochondrial dysfunction may be 
primarily dependent upon changes in the mitochondrial transcriptome resulting from nDNA 
damage rather than the direct mitotoxic effects(10), consistent with previous findings linking 
Dox-induced cardiotoxicity to a suppression of mitochondrial biogenesis response resulting from 
a decrease in nuclear-encoded members of the mitochondrial transcriptome.(12) Under many 
environmental stresses such as exercise or oxidative damage, cardiac cells are able to adjust to 
these circumstances by simply generating new, functional mitochondria through the process of 
mitochondrial biogenesis.(13) However, in the presence of nDNA damage upon Dox treatment, 
mitochondrial biogenesis is impaired resulting in the death of cardiomyocytes. (12) Organelle-
specific contributions of Dox toxicity have yet to be fully dissected, largely due to the lack of 
available tools for selectively targeting drugs to a single subcellular compartment until recent 
years. 
Aside from anthracyclines, mitochondrial dysfunction has also been associated with the 
mechanism of action for other chemotherapeutic agents such as cisplatin (14), which have been 
exploited in the development of new cancer therapeutics. (15-17) The susceptibility of cancer 
cells to mitochondrial disruption is due to metabolic changes in cancer cells associated with high 
rates of glycolysis, which does not occur in cells belonging to other tissues such as the heart. 
{Fulda, 2010 #29}(ref)  While the therapeutic potential of harnessing the mitochondrial 
disruptive effects of Dox has been contemplated for over a decade (18), only recently have 
specific molecular targeting strategies been employed to deliver Dox to mitochondria. Such 
strategies include liposome encapsulation (19), chemical conjugation of mitochondrial targeting 
moieties (20, 21) chemical modification (22), and nanoparticle encapsulation (23), all of which 
have demonstrated the capacity to induce cell death in cancer cells, validating this therapeutic 
strategy. Particularly promising is the ability of these targeted compounds to overcome clinically 
relevant resistance mechanisms that exist outside of mitochondria.(20-22) Previous work has 
demonstrated that mitochondria-targeted Dox (mtDox, see Figure 1A for structure) is able to 
inhibit TopoII activity in vitro, leading to the induction of apoptotic cell death in cancer cells, 
while evading resistance mechanisms such as the upregulation of Pgp efflux pumps in the 
cellular membrane. (20) This phenomenon has been observed for a number of targeted anticancer 
agents and is likely the result of direct mitochondrial sequestration.(24)  
We propose that by leveraging this targeting approach, we can probe and eliminate the 
aforementioned nuclear effects associated with Dox-induced cardiotoxicity.(20) As mtDox 
would only induce mtDNA damage and not nDNA, a mitochondrial biogenesis response can be 
induced to rescue H9c2 rat cardiomyocytes from cell death.(25) Upon treatment of H9c2 cells 
with mtDox, mitochondrial biogenesis was initiated, leading to a reduction or complete 
elimination of cellular dysfunctions linked to chronic anthracycline-induced cardiomyopathy. 
These findings demonstrate that mitochondrial targeting is a promising way to reduce the 
cardiotoxic nuclear effects in Dox-treated cardiomyocytes. This study also highlights the 
potential use of subcellular targeting to probe the organelle-specific contributions of secondary 
toxicity associated with drug treatment. 
Methods and Materials 
Cell Culture. A2780 and H9c2 (2-1) rat cardiomyocytes were obtained from ATCC. A2780 cell 
were cultured in RPMI-160 media (Sigma-Aldrich, St. Louis) supplemented with 10% (v/v) fetal 
bovine serum (FBS, Life Technologies). H9c2 and 143B cells were cultured in DMEM (Life 
Technologies) supplemented with 10% (v/v) FBS and containing 4.5 g/L D-Glucose and 110 
mg/L sodium pyruvate. 143B ρº cells (donated by Douglas Wallace, University of California, 
Irvine) were grown in DMEM (Life Technologies) supplemented with 10% (v/v) FBS and 
containing 4.5 g/L D-Glucose, 5 mg/mL uridine, and 100 mM sodium pyruvate. All cells lines 
were grown at 37 °C with 5% CO2 in T75 cm
2
 flask with vented caps (Sarstedt). 
Peptide and drug conjugate synthesis and characterization. Solid-phase synthesis, 
doxorubicin-peptide conjugation and purification were performed as briefly described.(ref) 
Briefly, peptides were synthesized using standard FMOC chemistry, succinic anhydride was then 
conjugated to the N-terminus of the peptide while on resin. The peptides were cleaved from resin, 
precipitated in ether, and lyophilized. Doxorubicin was then conjugated to the peptide in a 2:1 
molar ratio, using HBTU (3 equiv) and DIPEA (6 equiv.) in DMF overnight. The doxorubicin-
peptide conjugate was then purified using RP-HPLC on a preparative C18 column.  The identity 
of the final conjugate was confirmed using electrospray ionization mass spectrometry, and purity 
was determined to be > 95% using analytical RP-HPLC on a C18 column with a H2O-acetonitlre 
(0.1% TFA) gradient. Dox and mtDox concentrations were determined by absorbance in ddH2O 





Subcellular localization and DNA staining. Cells were seeded at a density of 25 000 cells/well 
(A2780 cells) or 12 500 cells/well (H9c2) in 8-well slides (iBidi, Germany), and grown one day 
in advance of experiments. The cells were treated with 8 µM Dox or mtDox for 1 hr in growth 
media (without FBS), and MitoTracker 633 (150 nM) (Life Technologies) or Hoechst (500 nM) 
were added for the final 15 min. Cells were rinsed twice with PBS, and then fixed in 4 % 
paraformaldehyde  and 1 % glutaformaldehyde in PBS for 15 min on ice. Cells were rinsed twice 
more with PBS, and then images in PBS using an inverted Zeiss Observer Z1 microscope. For 
DNA staining, 143B and 143B ρ° cells were plated to 50% confluency one day prior to imaging 
in 8-well slides (iBidi, Germany). Cells were treated with PicoGreen (Life Technologies, fixed, 
and imaged under the microscope. 
Quantification of subcellular uptake. H9c2 and A2780 cells were plated to 80% confluency in 
T75 cm
2
 flask with vented caps (Sarstedt). Cells were incubated with 4 µM Dox and mtDox for 2 
hr at 37 °C with 5% CO2 and subsequently harvested using 0.25% Trypsin-EDTA (Life 
Technologies). Nuclear, cytosolic, and mitochondrial fractions were isolated using Cell 
Fractionation Kit (MitoSciences) as per the manufacturer’s instructions. 50 µL of each fraction 
was added to 50 µL of 2 % triton x-100 (BioShop) in DMSO and 100 µL of 50% ethanol/0.3M 
hydrochloric acid in deionized water in triplicates on a white, opaque 96-well plate (Greiner Bio-
One) and shaken for 5 min. The fluorescence (excitation: 490 nm, emission: 590 nm) was 
measured on a spectrophotometer (SpectraMax) and the percentage of drug in each subcellular 
fraction was then calculated. 
Western blotting.  H9c2 and A2780 cells were plated to 80% confluency in T75 cm
2
 flask with 
vented caps (Sarstedt). Cells were incubated with 4 µM Dox and mtDox for 2 hr at 37 °C with 5% 
CO2 and subsequently harvested using 0.25% Trypsin-EDTA (Life Technologies). Following 
treatment, cells were rinsed twice with ice cold PBS and lysed with RIPA lysis buffer 
supplemented with PMSF and Protease/Phosphatise Inhibitor Cocktail (Cell signalling 
Technologies) for 30 min on ice with periodic vortexing. Cell lysates were then centrifuged at 16 
000 g for 10 min at 4 °C and the supernatant was collected. Total protein concentrations of each 
sample were determined using the BCA assay, and 20-40 µg of total protein were analyzed using 
4-12% gradient precast SDS-PAGE gels (Bio-Rad). Gels were transferred to PVDF membranes, 
and blocked in 5% milk (v/v) in TBST buffer a minimum of 2 hours. Membranes were then 
probed overnight with primary antibodies as follows; 1:1000 anti- γH2AX (Abcam) in 5% milk 
TBST and 1:500 glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Cell Signalling 
Technologies) in 5% milk TBST. Blots were rinsed 3 times with TBST and blotted with a 
secondary anti-rabbit IgG – HRP linked antibody (1:1000 for 2-6 hr in TBST), and bands were 
detected using standard chemiluminescence detection. 
Measurements of ATP levels, TCA cycle activity, and ETC activity. All measurements were 
performed as described previously.(ref)-…see attached file 
Flow cytometry measurement of cellular uptake, mitochondrial membrane potential, ROS 
and mitochondrial volume. Cells were seeded one day prior to treatment in 12 well flat bottom 
tissue culture plates (Corning, NY) at densities of 100 00 per well (A2780) or 50 000 per well 
(H9c2). All treatments were performed in culture medium without FBS. Following treatment 
with mtDox or Dox at 37 ºC, and with fluorescence probes as described for each experiment 
below, cells were trypsinized, rinsed twice with ice cold PBS. Cells were then stained will 
SYTOX Red (Life Technologies) for 10 min in order to exclude any dead cells from analysis, 
and were maintained on ice prior to analysis. Fluorescence was recorded on a BDFACSCanto 
flow cytometer (BD Biosciences). A minimum of 10 000 cells were analyzed for each sample, 
and mean fluoresce values were determined.  All dyes used in flow cytometer studies were 
chosen in order to minimize spectral overlap with fluorescence of the Doxorubicin moiety 
(concurrently measured in all experiments using a 488 nm laser excitation with wavelength 
filters to record emission in the range of 565-606 nm). For each dye spectral overlap with 
doxorubicin was assessed, and compensation values were obtained using the manufacturer’s 
protocols in order to correct fluorescence levels.   
Comparison of live cell/fixed overall cellular uptake. Following recording of fluorescence in live 
cells, sampled were pelleted by centrifugation and fixed with 4% PFA in PBS for 15 min on ice. 
Cells were rinsed twice with PBS and samples were recorded immediately under the same 
condition used prior to fixation. Test samples were also performed where cells were incubated in 
PBS in place of 4 % PFA, but otherwise treated in the same manner. The overall medium 
fluorescence of these samples was reduced by < 5 % between successive flow cytometry 
measurements. 
Mitochondrial membrane potential. During the final 30 min of treatment, DiOC6(3) (3,3'-
Dihexyloxacarbocyanine Iodide) (Life Technologies) was added cells to a final concentration of 
50 nM. Fluorescence of this dye was recorded using a 488 nm laser for excitation, and emission 
was recorded between 515 – 545 nm. 
Measurement of ROS. Following treatment, cells were stained with 5 µM H2DCFDA (Life 
Technologies) for 30 min at 37 C in PBS. Dye was then removed and cells were incubated in 
culture media at 37 C for an additional 30 min. Fluorescence of this dye was recorded using a 
488 nm laser for excitation, and emission was recorded between 515 – 545 nm. 
Mitochondrial volume. During the final 30 min of treatment, MitoTracker Deep Red FM (Life 
Technologies) was added to cells at a final concentration of 200 nM. SYTOX Red was not added 
to these samples for analysis due to spectra overlap. As such, dead cells and debris were 
excluded during analysis solely on the basis of forward and side scattering. 
Determination of mtDNA damage by qPCR. H9c2 and A2780 cells were plated to 80% 
confluency in T75 cm
2 flasks with vented caps or in 6-well plates (BD). Cells were incubated 
with indicated concentrations of Dox or mtDox for 6 or 24 hr at 37 °C with 5% CO2. Cells were 
then harvested using 0.25% Trypsin-EDTA (Life Technologies), and total DNA were isolated 
using AllPrep DNA/RNA Mini Kit (Qiagen) or GenElute mammalian genomic DNA miniprep 
kit (Sigma) as per the manufacturer’s instructions and quantified using PicoGreen (Life 
Technologies). An 8.9 kb mitochondrial segment of A2780 cells or a 3.4 kb mitochondrial 
segment of H9c2 cells was amplified using the Elongase long range PCR enzyme kit (Invitrogen) 
as per the manufacturer’s instructions and as previously described. (26) The PCR products from 
the treated samples were quantified in duplicates using PicoGreen (Life Technologies) and 
normalized to untreated sample. 
Analysis of cytotoxicity. A2780 cells were seeded in 96 well plates at 10 000 per well for time 
points > 24 hour, and at 1 000 per well for assessment of cell growth over 72 hours. H9c2 were 
seeded at 5 000 per well for time points > 24 hr, 3 000 per well for assessment of cell growth 
over 72 hour. Cells were treated in cell culture media without FBS for time points > 24 hr, and 
with FBS for 72 hr cell viability assay.  
Determination of mitochondrial protein levels. Cells were seeded in 96 well plates at density 
of 10 000 or 5 000 per well.  Cells were then treated with 4 µM Dox or 8 µM  mtDox in culture 
media without FBS, rinsed twice with PBS. Cell fixation, permeabilization, and ELISA was 
performed using the MitoBiogenesis™ In-Cell ELISA Kit (Colorimetric) (Abcam), according to 
manufacturer’s protocol. 
Measurement of mRNA levels of mitochondrial biogenesis markers by RT-qPCR. H9c2 
cells were plated to 80% confluency in T75 cm
2 flask with vented caps. Cells were incubated 
with 1 µM Dox or 8 µM mtDox for 6 hr at 37 °C with 5% CO2. Cells were then harvested using 
0.25% Trypsin-EDTA (Life Technologies), and total RNA were isolated using AllPrep 
DNA/RNA Mini Kit (Qiagen) as per the manufacturer’s instructions. RNA Quantification was 
performed on a spectrophotometer (NanoDrop) at 260 nm. 1-2 µg of total RNA was used for 
cDNA synthesis using gene specific primers for GAPDH, nuclear respiratory factor 1 (NRF1), 
and mitochondrial transcription factor A (TFAM) and SuperScript® III Reverse Transcriptase 
(Life Technologies) as per the manufacturer’s instructions. Amplification of cDNA was 
performed on qPCR (Applied Biosystems) using SYBR® Green PCR Master Mix (Life 
Technologies) in MicroAmp optical 96-well reaction plate (Life Technologies) as per the 
manufacturer’s instructions in duplicates.  
Determination of MTD and CK level. 6-7 week old male mice were used to evaluate the MTD 
of Dox and mtDox. Intraperitoneal injection of 3mg/kg of each compound was administered to 
10 mice per group daily for 5 days. All mice including those of the untreated group were 
weighed and observed daily. 24 hours following the 5th dose, 3 mice from each group were 
sacrificed and serum samples were taken. Creatine Kinase levels were measured from the blood 
samples following standard procedures. All mouse handling and blood chemistry work were 
performed by Innovative Medical Research. 
Results and Discussion 
mtDox uptake, localization and lack of nuclear damage in H9c2 cells. 
Our lab has previously demonstrated that mtDox (Figure 1A) localizes to mitochondria of 
both HeLa and A2780 human cancer cell lines (20).  In this study, the uptake and localization of 
untargeted Dox was compared to mtDox in a rat cardiomyocyte cell line (H9c2). By monitoring 
the inherent fluorescence of Dox, it was determined that the parent compound localizes almost 
entirely in the nucleus. In contrast, mtDox has a primarily mitochondrial distribution, as 
indicated by colocalization with a commercially available mitochondria-specific dye, 
MitoTracker Deep Red (Figure 1B). The subcellular uptake of Dox and mtDox was quantified by 
measuring the fluorescence recovered from the nucleus or mitochondria of H9c2 cells post 
treatment with each compound (Figure 1C).  In agreement with the microscopy images, mtDox 
was located almost entirely in mitochondria. Conversely, the majority of Dox was located in the 
nucleus with a smaller fraction localizing to mitochondria. In fact, the mitochondrial 
accumulation of Dox was similar to that achieved by mtDox in H9c2 cells. The levels of uptake 
of mtDox and Dox in the nucleus and mitochondrial were measured in A2780 cells, a human 
ovarian cancer cell line. In this cell line, while Dox had similar overall levels of uptake and 
distribution to H9c2 cells, mtDox had approximately double the uptake into mitochondria in 
comparison to the uptake achieved in H9c2 cells. 
Overall cellular uptake of both Dox and mtDox in live cells was monitored using flow 
cytometry. Using this technique, much lower relative levels of uptake of mtDox were observed 
than the subcellular fractionation studies indicated. However upon fixation of these cells with 
paraformaldehyde, a significant increase of fluorescence was obtained in the mtDox treated cells 
but not for Dox treated cells (Figure S1). As doxorubicin fluorescence is highly quenched by 
DNA, it is possible that mtDox localized within the mitochondrial matrix is quenched due to its 
interaction with mitochondrial DNA (mtDNA). To test this hypothesis, the fluorescence of 
mtDox in 143B ρ° cells which are depleted of mtDNA was monitored. Indeed the fluorescence 
of mtDox is not increased upon fixation in this cell line, but is in the parental 143B cell line 
which contains mtDNA. The absence of mtDNA in this cell line was confirmed by lack of 
PicoGreen staining of mitochondria (Figure S2). These observations serve to confirm that mtDox 
is localized in matrix of H9c2 mitochondria where it is able to interact directly with mtDNA. 
 The lack of any direct nuclear effect of mtDox was also confirmed by testing for the 
presence or absence of nDNA DSBs. The generation of DSBs resulting from TopoII poisoning in 
the nucleus has previously linked to be the major source of cardiotoxic effects of Dox. In H9c2 
cells, the presence of DSBs induced by Dox was confirmed by immunoblotting for γ-H2AX 
histone in the nucleus, a commonly used marker specific for nDNA lesions (Figure 1D). In 
contrast, no nDNA DSBs were observed for mtDox treated cells, despite its previously 
confirmed capacity to act as a TopoII poison. Likewise in A2780 cells, Dox, but not mtDox 
generated an increase of γ-H2AX above the baseline level. Overall, in H9c2 cells mtDox has 
equivalent mitochondrial uptake as Dox but lacks any nuclear localization and thus direct nDNA 
damage. This selective activity makes mtDox an excellent tool to probe the cardiotoxic effects 
resulting from mitochondrial dysfunction induced by Dox in the absence of any direct nuclear 
damage. 
Comparison of mitochondrial dysfunction and time course of damage 
To detect the presence of any direct induction of mitochondrial dysfunction, the ATP 
levels as well as the rate of tricarboxylic acid (TCA) activity of H9c2 cells was assessed upon 
treatment with Dox or mtDox (Figure 2A). Both compounds resulted in similar decreases in total 
ATP levels. A decrease in TCA cycle activity was also observed upon exposure to Dox, and to a 
higher degree with mtDox. The mitochondrial metabolic consequences of Dox and mtDox 
treatment were further analyzed by probing the flux of electrons through various complexes of 
the ETC (Figure 2B). For Dox, the overall reduction of ETC activity is solely attributed to a 
decrease of complex I activity, owing to its ability to redox cycle specifically with this 
protein.(ref) In contrast, mtDox is more promiscuous in its reduction of ETC flux and affects 
complex I and complex II+III. Surprisingly, there was an increase in activity at complex IV 
compared to baseline level. 
In order to efficiently generate ATP, ETC flux maintains a highly negative inward 
mitochondrial membrane potential. Upon treatment with mtDox, there is a drop in the 
mitochondrial potential that is evident after just 30 min of treatment (Figure S3). This explains 
the decrease in overall ATP levels despite the increased proton flux generated at Complex IV. 
Despite the comparable mitochondrial uptake, Dox does not induce a similar potential decrease; 
likely due to it only has a single positive net charge. 
Next, the ability of these compounds to induce mitochondria-specific damage over time 
was assessed. After six hours of exposure, both mtDox and Dox generated high levels of ROS in 
H9c2 cells (Figure 3A). While ROS levels increased over 24 hours for Dox, ROS levels of 
mtDox-treated cells returned to baseline level. On the contrary, in A2780 cells, there was no 
recovery of ROS levels following treatment with either Dox or mtDox over 24 hours. 
Using a PCR based assay, the levels of mtDNA damage were measured by amplifying a 
large segment of the mitochondrial genome.(26) In H9c2 cells, mtDNA damage was observed 
after 6 hours of treatment with either Dox or mtDox. In accordance with ROS levels, no mtDNA 
damage above baseline was detected after 24 hours in H9c2 cells treated with mtDox, whereas 
cumulative mtDNA damage was observed upon treatment with Dox (Figure 3B). This recovery 
of DNA damage within 24 hours was once again absent in A2780 cells treated with mtDox. The 
time course of ROS generation and presence of mtDNA lesions demonstrate that while similar 
levels of mitochondrial damage initially occur upon treatment with either compound, the damage 
induced by mtDox in cardiomycytes does not persist at 24 hours. These results indicate that in 
H9c2 cells, the initial mitochondrial dysfunction resulting from mtDox treatment is reverted by a 
compensatory mechanism, which is absent upon Dox treatment. 
Time course of cellular toxicity in cardiomyocytes versus cancer cells. 
Given the differences in persistence of mitochondrial damage between mtDox and Dox 
treated cells, we next sought to investigate how these trends would translate to overall cellular 
toxicity at several time points. Using a clonogenic cell viability assay, the LC50 values of Dox 
and mtDox at 2, 6, 24, and 72 hours were determined in H9c2 and A2780 cells. Dox induced 
significant cell death beginning at 24 hours, becoming increasingly toxic at 72 hours in both 
H9c2 and A2780 cells (Figure 4A). Despite similar levels of mitochondrial uptake in H9c2 cells, 
mtDox is much less toxic than Dox at 24 and 72 hour time points. At these time points which 
cells are able to divide, mtDox induces cell death at increasingly lower concentrations for only 
A2780 cells, however there is little cumulative toxicity toward cardiomyocytes. This finding 
suggests that nDNA damage is a key contributor toward the long-term toxicity of Dox in 
cardiomyocytes. In H9c2 cells, exposure to mtDox - although still inducing direct mitochondrial 
dysfunction and damage at levels similar to Dox- do not result in cell death. These results are 
consistent with the observed recovery of mitochondrial dysfunction over time in mtDox, but not 
Dox treated cardiomyocytes. Taken together, these results indicate that mtDox treated H9c2 cells 
are able to recover from mitochondrial damage in the absence of nDNA damage. 
When used clinically, Dox-induced cardiotoxicity is dose-dependent and cumulative over 
the treatment period or for many years following.(ref) As H9c2 cells appear to recover from 
mtDox treatment within 24 hours, it was of interest to investigate whether reduced toxicity 
would be observed upon successive dosing. In order to test this, the cells were treated with 1 µM 
of Dox, which leads to > 75% cell death over 72 hours.  Upon splitting the total dose into three 
equal fractions and treating H9c2 cells every 24 hours, the overall level of cell death remained 
the same (Figure 4B). This methodology was repeated with a total mtDox concentration of 16 
µM. When cells were treated in a single dose, there was nearly complete cell death after 72 hours 
of exposure. If this same total dose was given as three separate doses every 24 hours however, 
>50% of the cells were viable. This further supports the observation that H9c2 cells were indeed 
able to recover from exposure to mtDox while Dox treated cells were susceptible to cumulative 
damage. 
mtDox treatment induces mitochondrial biogenesis in cardiomyocytes 
One mechanism by which cells compensate for damaged mitochondria is by producing 
new, healthy mitochondria through mitochondrial biogenesis. In order to determine if this 
pathway is an important mechanism for reducing mtDox toxicity toward cardiomyocytes, 
changes in total mitochondria were monitored following 6 and 24 hours exposure to the two 
compounds (Figure 5A). Firstly, the mitochondrial volume was measured by staining drug 
treated cells with MitoTracker Deep Red. In mtDox treated cells, there is a significant increase in 
mitochondrial volume compared to untreated cells. Despite Dox treated cells displaying similar 
level of mitochondrial dysfunction to mtDox, there was no increase in mitochondrial volume. 
While an increase in number of mitochondria may compensate for the mitochondrial dysfunction, 
damaged mitochondria may also be removed through mitophagy. Indeed by inhibiting this 
pathway using 3-methyladanine, further increases in mitochondrial volume were observed 
(Figure S4). This indicates that there is some fraction of damaged mitochondria that are cleared 
by mitophagy concurrently with the increase in this organelle through mitochondrial biogenesis. 
In order to further validate these changes in mitochondrial number, levels of 
mitochondrial proteins were evaluated. Using an ELISA based assay, the relative levels of 
nuclear encoded (SDH-A) and mtDNA encoded (COXI) mitochondrial proteins were measured 
upon drug treatment since mitochondrial biogenesis requires the transcription and translation of 
both nDNA and mtDNA. Similar to what was observed for mitochondrial volume, mitochondrial 
protein levels increased in mtDox, but not Dox treated cells after 6 hours of exposure. 
Interestingly, the levels of both the mtDNA and nDNA encoded proteins were similar. This 
indicates that the lack of mitochondrial biogenesis induced by Dox treatment is not solely the 
consequence of mitochondrial dysfunction but is also dependent on the functional state of nDNA. 
In mammalian cells, an increase in ROS serves as a signal of mitochondrial stress to the 
nucleus. In response to this signal, transcription factors such as NRF1 and TFAM are 
upregulated to aid in the process of mitochondrial biogenesis.(Deblois ref). Therefore, the 
transcript levels of NRF1 and TFAM of Dox and mtDox treated H9c2 cells were quantified. 
While only NRF1 levels increased significantly compared to untreated with mtDox treated cells, 
both NRF1 and TFAM levels were 5-fold higher in mtDox treated cells compared to Dox. Taken 
together, these findings demonstrate the ability of mtDox to induce mitochondrial biogenesis in 
cardiomyocytes to ensure their survival while Dox, in the presence of nDNA damage, are unable 
to recover from mitochondrial dysfunction due to impaired mitochondrial biogenesis. 
Systemic and cardiac-specific toxicity in vivo is not observed with mtDox administration 
Finally, the overall in vivo toxicity in mice treated with Dox or mtDox was evaluated by 
determining MTD (maximum tolerated dose). At the dosing regimen of 3mg/kg/day for 5 days, 
Dox and mtDox treated mice maintained less than 10% weight loss (Figure 6A). Next, CK 
(creatine kinase) levels were measured in serum samples from treated mice as a marker for 
cardiac toxicity. Interestingly, only Dox treated mice had significant increase in CK levels 
compared to untreated mice (Figure 6B). In addition, Dox treated mice had CK levels ~8 fold 
higher than that of untreated and ~4 fold higher than that of mtDox treated mice. These findings 
demonstrate that mtDox does not induce systemic or cardiac-specific toxicity in mice in 
accordance with the in cellulo data.  
Conclusions 
Given the off-target toxicity of Dox, it is an attractive proposition to produce derivatives 
of this drug with specific subcellular activity in an effort to maintain toxicity against cancer cells 
but reduce unwanted secondary toxicity in normal cells. The nuclear effects of Dox were 
eliminated through mitochondrial sequestration, allowing us to selectively study the importance 
of nDNA damage in cardiomyocyte toxicity upon drug treatment. In this study, we demonstrated 
that mitochondria-targeting significantly reduced toxicity of Dox toward cardiomyocytes, in 
accordance with recent reports in animal models that show nDNA damage plays a major role in 
anthracycline-induced cardiotoxicity. Although short-term mitochondrial dysfunction was 
observed in cardiomyocytes upon treatment with mtDOX, these effects were compensated for by 
mitochondrial biogenesis and do not persist at treatment concentrations where this compound 
exhibits anticancer activity. As demonstrated previously by the ability of mtDox to evade 
resistance mechanisms, combined with its reduced toxicity in cardiomyocytes and mice, 
mitochondria-targeting presents a promising strategy for the development of novel 
chemotherapeutics. Thus, subcellular targeting of Dox enables us to simultaneously study and 
eliminate the key cellular mechanism of cardiotoxicity. Furthermore, targeted compounds are 
powerful tools that can be used to deconvolute the organelle-specific effects for drugs that 
possess a wide range of cellular activity. A greater understanding of these cellular mechanisms 
will allow for the development of new pharmaceutical intervention strategies that have the ability 




decrease in mito potential activates nuc signalling pathway and then p53(27) 
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Figure 1. Comparison of uptake, subcellular localization and induction of nuclear damage. (A) 
The chemical structure of doxorubicin conjugated to a mitochondria-penetrating peptide (mtDox) 
(B) Subcellular localization of Dox (top row) and mtDox (bottom row) in H9c2 cardiomyocytes. 
Intrinsic Dox fluorescence (green channel) demonstrates nuclear staining, as indicated by co-
localization with Hoescht (blue channel in merge). mtDox accumulates in mitochondria as 
indicated by colocalization with MitoTracker Deep Red (red channel). (C) Quantification of 
relative levels of accumulation of 4 µM Dox or mtDox in nuclear or mitochondrial fractions of 
H9c2 (left panel) or A2780 (right panel). Uptake is shown as a percentage of total amount of 
compound used to treat cells. Mean values are plotted and error bars represent SEM. (D) 
Western blot of γ-H2AX and GAPDH (loading control) of H9c2 (left panel) of A2780 (right 
panel) cells treated with Dox (4 µM in A2780 cells, 4 µM in H9c2 cells) or mtDox (4 µM in 

















































































Figure 2. Mitochondrial dysfunction induced by drug treatment. (A) Measurement of ATP level 
and TCA activity upon treatment of H9c2 cells with 5 µM of Dox or mtDox. (B) Determination 
of Complex I-IV activity of ETC in H9c2 cells treated with 5 µM of Dox or mtDox. Mean values 
are plotted for all experiments and error bars represent SEM. Student’s t test, versus untreated 
control *p < 0.05.  
 
Figure 3. Induction and recovery of mitochondrial specific damage. (A) Relative levels of total 
cellular ROS following 6 or 24 hour treatment of H9c2 (left panel) or A2780 (right panel) with 
Dox or mtDox. Total fluorescence values of a ROS sensitive dye were normalized to untreated 
controls. (B) Relative PCR amplification of mtDNA damage following 6 or 24 hour treatment of 
H9c2 (left panel) or A2780 (right panel) with Dox or mtDox normalized to untreated cells. Mean 
values are plotted for all experiments and error bars represent SEM. Student’s t test, versus 




Figure 4. Time course of cell death of H9c2 versus A2780. (A) LC50 values following treatment 
with Dox (left panel) or mtDox (right panel) in H9c2 and A2780 cells. (B) Comparison of cell 
viability following single or 3 dispersed dosing over 72 hours with Dox or mtDox in H9c2 cells. 
Mean values are plotted for all experiments and error bars represent SEM. Student’s t test, versus 




Figure 5. Induction of mitochondrial biogenesis upon mtDox treatment. (A) Measurement of 
mitochondrial volume following 6 hour treatment with Dox or mtDox. (B) Comparison of 
mitochondrial protein levels by ELISA immunological assay following a 6 hour treatment with 
Dox or mtDox. (C) Quantification of transcript levels by RT-qPCR following 6 hour treatment 
with Dox or mtDox, normalized to untreated control. All of these experiments were analyzed by 
Mean values are plotted for all experiments and error bars represent SEM. Student’s t test, versus 
untreated control *p < 0.05, versus mtDox ºp < 0.05.   
 
Figure 6. Evaluation of general and cardiac-specific toxicity. A) Determination of MTD 
(maximum tolerated dose). Compounds were administered intraperitoneally daily for 5 days (n = 
5-10). MTD values of each compound was estimated based on the threshold at which all of the 
mice survived with a body weight loss < 10%. B) Measurement of CK (creatine kinase) level in 
treated mice. Serum was collected 24 hours after the 5th dose and (n = 3). Mean values are 
plotted for all experiments and error bars represent SEM. Student’s t test, versus untreated 





Figure S1. Ratio of total cellular fluorescence prior to and following cell fixation with 
paraformaldyehyde. Results are shown for H9c2 cardiomyocytes, 143B cells and 143B rho0 cells 
(mtDNA has been depleted by chronic treatment with ethidium bromide). 
 
Figure S2. Comparison of mtDNA content by fluorescence microscopy using PicoGreen dye. 
  
Figure S3. Relative mitochondrial potential following drug treatment. Levels of uptake of a 
mitochondrial potential sensitive dye were normalized to untreated controls. 
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